Related Experiment Video
Updated: Feb 7, 2026

Measurement of Tissue Oxygenation Using Near-Infrared Spectroscopy in Patients Undergoing Hemodialysis
Published on: October 2, 2020
Pulmonary Hypertension: An Emerging Problem in Patients Undergoing Regular Hemodialysis
Aurangzeb Afzal1, Muhammad Asim Bhatti2, Shumaila Manzoor3
1Department of Nephrology, Lahore General Hospital, Lahore.
Objective:
To find out the frequency of pulmonary hypertension (PH) and its association with various contributing factors in patients undergoing regular hemodialysis (HD) due to end-stage renal disease (ESRD).
Study Design:
Cross-sectional analytical study.
Place And Duration Of Study:
Nephrology Department, Lahore General Hospital, Pakistan, from July to December 2016.
Methodology:
Fifty patients with end-stage renal disease. Various parameters, including the pulmonary arterial systolic pressure (PASP), were recorded. Pulmonary arterial pressure greater than 25 mmHg at rest was defined as pulmonary hypertension. It was further divided into three sub categories as mild (25-40 mmHg), moderate (40-55 mmHg), and severe (greater than 55 mmHg). Data were correlated with age, gender, body mass index, systemic hypertension, diabetes, duration of dialysis, and Hb (hemoglobin) concentration. Data was analysed using SPSS version 23.0.
Results:
The median (IQR) duration of dialysis was 12 (11.25) months. Eighteen (36%) patients were found to have PH. It is greater in patients who had been on dialysis for more than 5 months. A positive association was seen between the duration of dialysis and the prevalence of PH (p=0.024).
Conclusion:
A considerable number of patients on hemodialysis have pulmonary hypertension which is associated with the longer duration of maintenance hemodialysis.
Related Concept Videos
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Hemodialysis I: Introduction
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...

